TICKERNERD
Menu
ALVOALVOHealthcare · Drug Manufacturers - Specialty & Generic

ALVO Stock Forecast: Alvotech Price Predictions for 2026-2027

Last close, 11 Sept 2026
$5.31
+1.34% on the day

The 7 Wall Street analysts covering Alvotech hold a median 12-month price target of $6 — +13.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.9B
Ticker Nerd rank
29 / 100
Median analyst target
$6.00
Analysts covering
7
Revenue$105.8M−38.9% y/y
Operating income−$11.7M
Net income−$66.8M
Free cash flow−$64.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.3%
1M
+39.7%
YTD
+3.5%
1Y
−34.0%
From 52W high
−40.9%
From 52W low
+77.0%
$3.00
$8.98
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ALVO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Alvotech on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
29 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
95
Value
89
Volatility
77
Revisions
39
Size
35
Growth
25
Accruals
21
Momentum
16
Issuance
12

Quality (95): The business earns solid, repeatable profits on what it owns.

Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ALVO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALVO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$3.00$4.00$5.00$6.00$7.00$8.00$9.00Oct 25Jan 26Apr 26Jul 26ALVOHigh $9.00Median $6.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
5 Buy1 Hold1 Sell
Low $4.00Median $6.00High $9.00

The green dot is the last close — the median target sits +13.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 Aug 2026B of A SecuritiesInitiatesBuy$7.00
14 Aug 2026Evercore ISI GroupInitiatesOutperform—
14 Aug 2026Evercore ISI GroupInitiatesOutperform—
24 Mar 2026BarclaysMaintainsUnderweight—
24 Mar 2026BarclaysMaintainsUnderweight$5.00 → $4.00
24 Mar 2026UBSMaintainsBuy—
24 Mar 2026UBSMaintainsBuy$10 → $6.00
9 Dec 2025BarclaysInitiatesUnderweight—
18 Nov 2025UBSMaintainsBuy—
4 Nov 2025Deutsche BankDowngradeHold—
14 Oct 2025Morgan StanleyUpgradeOverweight—
23 Sept 2025Deutsche BankUpgradeBuy—
18 July 2025UBSMaintainsBuy—
14 Feb 2025UBSInitiatesBuy—
25 July 2024BarclaysMaintainsOverweight—
24 May 2024BarclaysMaintainsOverweight—
22 Mar 2024BarclaysMaintainsOverweight—
29 Jan 2024BarclaysUpgradeOverweight—
20 Oct 2023CitigroupUpgradeNeutral—
21 Sept 2023BarclaysInitiatesEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALVO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ALVO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Alvotech returned −34.0% against +17.5% for the S&P 500, dividends included.

ALVO vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26ALVOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ALVO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−186.2%
Analysts raising
0
Analysts cutting
1
Fundamentals

Alvotech (ALVO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
42.4×

Cheaper than 17% of US stocks

Price / sales
3.8×

Cheaper than 33% of US stocks

Price / book
−5.9×

Cheaper than 97% of US stocks

EV / EBITDA
42.2×

Cheaper than 6% of US stocks

Growth & margins
Revenue growth (YoY)
−38.9%

Higher than 7% of US stocks

Earnings growth (YoY)
−38.9%

Higher than 13% of US stocks

Gross margin
50.7%

Higher than 63% of US stocks

Operating margin
−11.1%

Higher than 24% of US stocks

Net margin
−36.3%

Higher than 12% of US stocks

Returns & dividend
Return on equity
−9.8%

Higher than 36% of US stocks

Return on assets
2.2%

Higher than 60% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Alvotech (ALVO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Alvotech has a market value of $1.9B and an enterprise value of $3.2B.

  • Revenue in the twelve months to 30 June 2026: $492.0M. The latest quarter shrank 38.9% year on year.

  • Net income over the same four quarters: −$179.6M, a −36.5% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$333.8M.

  • Shares outstanding: 356.8M.

  • Trailing P/E: 42.4×; forward P/E: 23.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Alvotech employs 1,279 people — $385K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

ALVO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ALVOAlvotech$1.9B
29
BCRXBioCryst Pharmaceuticals, Inc.$2.0B
87
BHCBausch Health Cos., Inc.$2.2B
96
TRLVTrulieve Cannabis Corp.$2.2B
83
PBHPrestige Consumer Healthcare, Inc.$2.3B
58
PRGOPerrigo Co. Plc$1.9B
76
SUPNSupernus Pharmaceuticals, Inc.$2.4B
79

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Alvotech — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ALVO news & analysis

Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations

GlobeNewsWire · 31 Aug 2026positive

Alvotech announced that the U.S. FDA has accepted for review a Biologics License Application for AVT80, a proposed interchangeable biosimilar to Entyvio (vedolizumab) in prefilled syringe and autoinjector forms for subcutaneous administration. This expands Alvotech's proposed biosimilar program for Entyvio to subcutaneous presentations.

Why it matters — The FDA acceptance marks progress in Alvotech's biosimilar development efforts and broadens its proposed Entyvio biosimilar program to include subcutaneous presentations, a development of interest to Alvotech watchers.

Alvotech to present at upcoming investor conferences in September

GlobeNewsWire · 27 Aug 2026neutral

Alvotech announced that Founder and Chairman Robert Wessman and Chief Strategy Officer Dr. Balaji V. Prasad will participate in upcoming investor conferences in September. The company noted the participation in a press release dated August 27, 2026.

Why it matters — For Alvotech watchers, executive participation at investor conferences signals increased management visibility and opportunities to communicate the company's biosimilar strategy to investors.

Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets

GlobeNewsWire · 21 Aug 2026positive

Alvotech announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical covering two of its biosimilar candidates—AVT34 (proposed biosimilar to durvalumab) and AVT87 (proposed biosimilar to emicizumab)—for the United States and selected Asian markets.

Why it matters — The agreement expands the commercial reach of Alvotech's pipeline candidates into the U.S. and Asian markets through a partnership with Lotus Pharmaceutical.

Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts

Seeking Alpha · 20 Aug 2026neutral

Alvotech maintains a Hold rating amid missed H1 2026 earnings and regulatory challenges, despite pipeline progress. FDA CRLs for AVT05 and AVT06 were attributed to manufacturing issues that have been addressed, with BLAs resubmitted and multiple approvals targeted for Q4 2026, while AVT06 has global commercialization rights secured post-November 2026.

Why it matters — Alvotech watchers would care because the resubmitted BLAs for AVT05 and AVT06, with approvals targeted for Q4 2026 and AVT06's secured global commercialization rights, represent key upcoming catalysts for the company's pipeline.

Alvotech (ALVO) Q2 2026 Earnings Call Transcript

Seeking Alpha · 20 Aug 2026neutral

Seeking Alpha published the transcript of Alvotech's (ALVO) Q2 2026 earnings call. The excerpt confirms the transcript of the company's second-quarter 2026 earnings call is now available.

Why it matters — The transcript provides ALVO watchers with a record of management's discussion of the company's second-quarter 2026 results and outlook.

FAQ

Frequently asked questions about ALVO stock

What is the ALVO stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Alvotech have a median 12-month price target of $6, with estimates ranging from $4 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALVO stock a buy right now?

Of the 7 analysts covering Alvotech, 5 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Alvotech 29 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALVO?

As at 12 Sept 2026, Alvotech ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (95 of 100).

Will ALVO stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +13.0% from the last close, and Ticker Nerd's factor model ranks Alvotech 29 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALVO stock forecast for 2030?

No analyst covering Alvotech publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALVO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $9 over the next 12 months.

How has ALVO stock performed over the past year?

Alvotech returned -34.0% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Alvotech do?

Alvotech SA is a biotechnology company focused on the development and manufacture of biosimilar medicines. Alvotech SA specializes in creating high-quality, cost-competitive alternatives to established biologic therapies, with products and candidates spanning autoimmune diseases, eye disorders, osteoporosis, respiratory disease, oncology, and other therapeutic areas.

What is the latest news on ALVO?

The most recent item we track (GlobeNewsWire, 31 Aug 2026): "Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations". Alvotech announced that the U.S. FDA has accepted for review a Biologics License Application for AVT80, a proposed interchangeable biosimilar to Entyvio (vedolizumab) in prefilled syringe and autoinjector forms for subcutaneous administration. This expands Alvotech's proposed biosimilar program for Entyvio to subcutaneous presentations.

Company

About Alvotech.

Alvotech SA is a biotechnology company focused on the development and manufacture of biosimilar medicines. Alvotech SA specializes in creating high-quality, cost-competitive alternatives to established biologic therapies, with products and candidates spanning autoimmune diseases, eye disorders, osteoporosis, respiratory disease, oncology, and other therapeutic areas. The company operates a vertically integrated model that covers the biosimilar value chain from cell line development and research to commercial manufacturing. Its portfolio includes monoclonal antibodies and fusion proteins designed to support treatment access across global patient markets. Alvotech SA works through strategic partnerships to extend commercialization and distribution reach across North America, Europe, Asia, and other international markets. Headquartered in Luxembourg, Alvotech SA plays a role in expanding access to biosimilar medicines within the global biopharmaceutical sector.

CEO Mr. Robert Wessman · 1,279 employees · Luxembourg · https://www.alvotech.com